CEO Dr. Robin Smith of NeoStem to Discuss Agreement to Acquire California Stem Cell, Inc. Live Today on Clear Channel's "The Traders Network Show"

NEW YORK, NY--(Marketwired - Apr 15, 2014) - NeoStem, Inc. (NASDAQ: NBS) ("NeoStem"), a leader in the emerging cellular therapy industry, announced today that Chairman and CEO, Dr. Robin Smith, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. In this exclusive 2-segement interview, Dr. Smith will go over the strategic details of their contract to acquire California Stem Cell, Inc. (CSC) .

We encourage shareholders, analysts, industry professional and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.

Date: Tue, April 15, 2014
Start Time:  11:30am PDT | 1:30pm CDT | 2:30pm EDT (U.S.)
Network: Clear Channel
Station: DFW 1190AM KFXR
Show: The Traders Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Clear Channel: Clear Channel's Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About Michael Yorba:

Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has produced and hosted The Traders Network Show broadcasted live daily on Clear Channel DFW 1190AM KFXR from 1pm - 3pm CT, Monday-Friday.

Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It's a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more... shift your thinking and join us as we deliver "tomorrow's ideas today" on Clear Channel's The Traders Network Show.

About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's ability to consummate the CSC acquisition and the Company's ability to develop and grow its business, the successful development of cellular therapies, including with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's CD34 Cell Program and T Regulatory Cell Program and other cell therapies (including Melapuldencel-T if CSC is successfully acquired), the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

A www.1800PublicRelations.com PR Event